Eli Lilly is dropping CVS Health's drug benefit plan for its employees after the healthcare conglomerate stopped covering the company's weight-loss drug in favor of Novo Nordisk's rival medication, ...

Eli Lilly (LLY) drops CVS Health's (CVS) drug plan after the health insurer limited access to its obesity drug, Zepbound in favor of Novo's (NVO) Wegovy. Read more here.

Eli Lilly is ending its employee drug benefit plan with CVS Health after CVS favored Novo Nordisk's weight-loss drug over ...

Trividia Health, Inc., announced today that it’s TRUE METRIX ® Self-Monitoring Blood Glucose Systems are now preferred for ...

As many small businesses weigh their options for health coverage for the new year, the Indiana Chamber of Commerce has a new offering.

Although alleged oversight claims are not uncommon, this case was unusual because the claims were not asserted derivatively ...

CVS Health management raised 2025 EPS guidance, projecting robust double-digit earnings growth. Click here to read why CVS stock is a Buy.

Philadelphia has sued major pharmacy benefit managers, alleging their marketing and distribution of opioids contributed to ...

High-rolling investors have positioned themselves bearish on CVS Health (NYSE:CVS), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Q3 2025 Earnings Call Transcript October 29, 2025 CVS Health Corporation beats earnings expectations. Reported EPS is $1.6, ...